DYN net incomeQ3 2026-$193.55M
DYN net income was -$193.55M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$108.04M a year earlier. For the full fiscal 2025 it was -$446.21M, compared with -$317.42M in fiscal 2024.
Dyne Therapeutics Inc. (DYN) financials
For the twelve months ended Sep 30, 2026, Dyne Therapeutics Inc. reported -$604.92M of net income.
- Net income, TTM
- -$604.92M
- Free cash flow, TTM
- -$568.76M
- Cash
- $913.20M
- Total debt
- $200.01M
- Market cap
- $3.36B
FY2019FY2025
FY2019FY2025
DYN revenue and earnings growth
DYN EPSQ3 2026-$1.06
DYN diluted EPS was -$1.06 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.76 a year earlier. For the full fiscal 2025 it was -$3.47, compared with -$3.37 in fiscal 2024.
DYN free cash flowQ3 2026-$179.50M
DYN free cash flow was -$179.50M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$91.17M a year earlier. For the full fiscal 2025 it was -$405.13M, compared with -$294.75M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $398.33M | $281.41M | $210.76M | $142.76M | $121.31M | $45.20M | $11.04M |
| Selling, general and admin | $69.85M | $62.48M | $31.40M | $28.20M | $28.72M | $13.45M | $2.79M |
| Operating income | -$468.18M | -$343.89M | -$242.16M | -$170.96M | -$150.03M | -$58.65M | -$13.83M |
| Income tax | $0 | $0 | $0 | - | - | - | - |
| Net income | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -$149.29M | -$59.44M | -$14.86M |
| EPS, basic | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | -$6.08 |
| EPS, diluted | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | -$6.08 |
| Diluted shares | - | - | - | - | 50.9M | 14.4M | 2.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $893.37M | $435.45M | $121.63M | $172.15M | $200.82M | $300.85M | $14.63M |
| Current assets | $1.13B | $659.28M | $129.38M | $265.59M | $382.39M | $349.09M | $14.76M |
| Total assets | $1.19B | $691.23M | $165.08M | $306.32M | $425.66M | $353.33M | $16.44M |
| Current liabilities | $50.63M | $42.26M | $51.09M | $28.09M | $28.72M | $10.97M | $2.36M |
| Total debt | $148.92M | $0 | - | - | - | - | - |
| Total liabilities | $214.83M | $61.40M | $73.79M | $53.96M | $57.47M | $10.97M | $2.40M |
| Shareholders' equity | $972.13M | $629.84M | $91.29M | $252.36M | $368.20M | $342.37M | $14.04M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$403.21M | -$292.37M | -$188.16M | -$153.65M | -$119.56M | -$46.51M | -$11.83M |
| Capital expenditures | $1.92M | $2.38M | $729.0K | $3.07M | $3.62M | $1.16M | $1.65M |
| Free cash flow | -$405.13M | -$294.75M | -$188.89M | -$156.71M | -$123.18M | -$47.67M | -$13.48M |
| Investing cash flow | -$28.75M | -$204.08M | $83.31M | $87.20M | -$137.89M | -$45.66M | -$1.65M |
| Financing cash flow | $890.31M | $809.89M | $54.32M | $37.39M | $157.82M | $380.69M | $19.99M |
| Stock-based compensation | $45.85M | $45.86M | $19.97M | $15.18M | $17.54M | $6.59M | $26.0K |
| Depreciation and amortization | $2.05M | $1.67M | $1.67M | $1.68M | $1.09M | $700.0K | $271.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Return on equity | -45.9% | -50.4% | -258.4% | -66.6% | -40.5% | -17.4% | -105.9% |
| Return on assets | -37.6% | -45.9% | -142.9% | -54.9% | -35.1% | -16.8% | -90.4% |
| Current ratio | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 | 31.83 | 6.26 |
| Debt to equity | 0.15 | 0.00 | - | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $161.74M | $152.17M | $100.89M | $95.43M | $97.22M | $99.24M | $106.45M | $81.81M | $92.80M | $62.26M | $44.54M | $58.84M |
| Selling, general and admin | $35.33M | $29.49M | $24.39M | $20.70M | $16.67M | $16.55M | $15.93M | $15.30M | $12.86M | $9.70M | $24.62M | $8.84M |
| Operating income | -$197.07M | -$181.66M | -$125.28M | -$116.13M | -$113.89M | -$115.79M | -$122.37M | -$97.11M | -$105.57M | -$71.96M | -$69.16M | -$67.69M |
| Interest expense | - | - | - | - | $2.90M | $94.0K | $0 | - | $0 | - | - | - |
| Net income | -$193.55M | -$178.56M | -$120.85M | -$111.95M | -$108.04M | -$110.86M | -$115.36M | -$89.54M | -$97.13M | -$65.10M | -$65.65M | -$66.64M |
| EPS, basic | -$1.06 | -$1.08 | -$0.73 | - | -$0.76 | -$0.97 | -$1.05 | - | -$0.96 | -$0.70 | -$0.81 | - |
| EPS, diluted | -$1.06 | -$1.08 | -$0.73 | - | -$0.76 | -$0.97 | -$1.05 | - | -$0.96 | -$0.70 | -$0.81 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $913.20M | $676.11M | $753.10M | $893.37M | $573.61M | $485.04M | $472.25M | $435.45M | $532.16M | $608.20M | $272.04M | $121.63M |
| Current assets | $1.18B | $937.89M | $1.02B | $1.13B | $806.26M | $697.95M | $689.50M | $659.28M | $736.39M | $792.32M | $488.14M | $129.38M |
| Total assets | $1.23B | $994.01M | $1.08B | $1.19B | $867.06M | $728.99M | $721.07M | $691.23M | $768.84M | $825.88M | $522.28M | $165.08M |
| Current liabilities | $90.55M | $78.03M | $51.25M | $50.63M | $59.85M | $41.47M | $33.88M | $42.26M | $43.26M | $29.75M | $22.36M | $51.09M |
| Total debt | $200.01M | $199.33M | $149.38M | $148.92M | $99.15M | $98.81M | - | $0 | - | - | - | - |
| Total liabilities | $303.87M | $291.86M | $214.90M | $214.83M | $175.28M | $157.55M | $52.10M | $61.40M | $63.30M | $50.69M | $44.22M | $73.79M |
| Shareholders' equity | $930.93M | $702.15M | $865.05M | $972.13M | $691.78M | $571.45M | $668.97M | $629.84M | $705.54M | $775.19M | $478.06M | $91.29M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$177.49M | -$130.29M | -$144.92M | -$111.83M | -$90.78M | -$94.70M | -$105.89M | -$84.33M | -$74.63M | -$54.87M | -$78.54M | -$35.01M |
| Capital expenditures | $2.01M | $1.51M | $221.0K | $484.0K | $395.0K | $60.0K | $981.0K | $1.07M | $253.0K | $857.0K | $191.0K | $82.0K |
| Free cash flow | -$179.50M | -$131.80M | -$145.14M | -$112.32M | -$91.17M | -$94.76M | -$106.87M | -$85.41M | -$74.88M | -$55.73M | -$78.73M | -$35.09M |
| Investing cash flow | -$1.29M | -$4.79M | -$2.39M | $982.0K | -$37.97M | $6.77M | $1.46M | -$16.01M | -$19.40M | $11.17M | -$179.84M | $26.20M |
| Financing cash flow | $418.10M | $58.11M | $7.06M | $430.96M | $217.33M | $100.77M | $141.24M | $3.64M | $18.01M | $379.86M | $408.39M | $147.0K |
| Stock-based compensation | $16.21M | $14.98M | $13.08M | $11.23M | $11.08M | $10.52M | $13.02M | $10.48M | $8.74M | $6.74M | $19.91M | $5.73M |
| Depreciation and amortization | $600.0K | $600.0K | $550.0K | $521.0K | $500.0K | $500.0K | $502.0K | $450.0K | $400.0K | $400.0K | $386.0K | $399.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 12.99 | 12.02 | 19.92 | 22.25 | 13.47 | 16.83 | 20.35 | 15.60 | 17.02 | 26.63 | 21.83 | 2.53 |
| Debt to equity | 0.21 | 0.28 | 0.17 | 0.15 | 0.14 | 0.17 | - | 0.00 | - | - | - | - |
Source: XBRL data Dyne Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DYN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DYN | - | - | -$604.92M | - | $3.36B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
DYN FAQ
5 questionsIs DYN profitable?
No. Dyne Therapeutics Inc. reported a net loss of $604.92M for the twelve months ended Sep 30, 2026.How much cash and debt does DYN have?
Dyne Therapeutics Inc. reported $913.20M in cash and cash equivalents and $200.01M of debt on its most recent balance sheet in SEC filings.What is DYN free cash flow?
Dyne Therapeutics Inc. generated -$568.76M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$564.53M less capital expenditures.When did DYN last report financial results?
The latest statements here come from Dyne Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this DYN financial data come from?
Quantisnow builds these statements from the structured XBRL data Dyne Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.